{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-025148","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.320837+00:00","generated_at":"2026-06-23T08:49:38.313274+00:00","sec_items":["7.01","5.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns","bullets":["EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.","Aurinia to receive $30M milestone payment from Otsuka for EC approval; cash within 30 days of invoicing.","Director Timothy P. Walbert resigns from Board effective Sept. 19, 2022; no disagreement with company.","LUPKYNIS previously received FDA approval in Jan. 2021 for same indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-025148","json":"https://secwatch.observer/filing/0001628280-22-025148.json","markdown":"https://secwatch.observer/filing/0001628280-22-025148.md","text":"https://secwatch.observer/filing/0001628280-22-025148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/0001628280-22-025148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/auph-20220919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:49:38.313274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2497ce412","claim":"Timothy P. Walbert resigned as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/0001628280-22-025148-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}